Targeting TIGIT Roche Class 1 heavyweights has been approved clinically in China for developing the new drug Tiragolumab.

On August 25, China's State Drug Administration's Drug Review Center (CDE) announced that Roche's Class 1 bio-new drug, Tiragolumab, has been approved for clinical trials to develop an adaptive disorder called: a joint treatment with atili-juju monotherapy for non-removable local late-stage relapse or metastatic esophageal squamous cancer.
is a monoclonal antibody targeting T-cell immunoglobulins and ITIM domain proteins (TIGIT) and is the first clinically approved clinical in China and is in phase 3 clinical studies worldwide.
screenshot Source: CDE.com Tiragolumab is an all-humanized monoclonal antibody developed by Roche.
TIGIT is an inhibitory subject that is highly expressed in tumor-immersed T-cells of multiple cancer types and inhibits the activation of T-cells by binding to CD226 competition and PPR, disrupting the activation of CD226.
In China, a number of enterprises have invested in TIGIT antibody research and development, approved clinical Xinda biological IBI939 (phase 1 in research) and Baiji Shenzhou BGB-A1217 (phase 1 in research), pre-clinical has Fuhong Hanxuan HLX53, Regency biology JS006 and Stanwei biological mAb-7 three in the study of TIGIT antibodies.
According to the Clinicaltrials.gov website, Tiragolumab is currently conducting 11 clinical trials for non-small cell lung cancer (phase 3 in research), small cell lung cancer (phase 3 in research), stomach adenocarcinoma, gastroesophageal junction cancer, esophageal cancer (Ib/II in research) and pancreatic cancer (in phase Ib/II in research).
studies have shown that Tiragolumab can be used to inhibit TIGIT activity and to demonstrate consistent safety and tolerance in conducted clinical trials.
Tiragolumab is currently the fastest-growing TIGIT inhibitor in the world.
June 8 this year, Roche submitted a clinical trial application for Tiragolumab in China.
this time, for the first time the product was approved clinically in China, it is proposed to develop an adaptive disorder for non-removable local late recurrence or metastatic esophageal squamous cancer.
the first-line treatment of patients with advanced or metastatic esophageal squamous cancer had a poor prognostic period, and there were fewer follow-up treatment options.
china accounts for nearly half of the world's esophageal cancer incidence and death, according to the 2017 Global Burden of Disease Study.
70% of esophageal cancer patients in China are in the middle and late stages, and more than 90% of histological types are squamous cancers.
references: The Drug Review Center of the State Drug Administration. Retrieved 2020-08-25, from. #